Biotech Unusual Volume Stocks: Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF), China Biologic Products Inc. (NASDAQ:CBPO), Protalix BioTherapeutics Inc. (NYSEMKT:PLX), Receptos Inc. (NASDAQ:RCPT), Acorda Therapeutics Inc. (NASDAQ:ACOR)
Can-Fite BioPharma Ltd. (NYSEMKT:CANF) a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced it has finalized enrolment in its Phase II/III trial of CF101 for the treatment of psoriasis with over 300 patients through 17 clinical centres in the U.S., Israel and Europe. Top line results from the trial are expected in the first quarter of 2015. Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) weekly performance is -3.04%. On last trading day company shares ended up $3.83. Analysts mean target price for the company is $28.00. distance from 50-day simple moving average (SMA50) is -17.01%.
China Biologic Products (NASDAQ:CBPO) shares fell in late trading after the biopharmaceutical company said it plans to sell shares of its common stock in a public offering. The company has granted the underwriters a 30-day option to buy up to 481,875 additional shares of common stock. China Biologice intends to use the proceeds that it receives from the offering primarily for general corporate purposes, in addition to potential acquisition or investment opportunities. China Biologic Products Inc. (NASDAQ:CBPO) shares fell -11.37% in last trading session and ended the day on $42.11. CBPO gross Margin is 67.60% and its return on assets is 18.80%.China Biologic Products Inc. (NASDAQ:CBPO) quarterly performance is 16.97%.
On June 18, 2014, Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) issued a press release announcing that the first Gaucher patient has been enrolled in the Company’s phase IIa clinical trial of oral glucocerebrosidase (GCD) (PRX-112) for the treatment of Gaucher disease. Protalix BioTherapeutics Inc. (NYSEMKT:PLX) shares moved up 6.48% in last trading session and was closed at $4.11, while trading in range of $3.87 – $4.13. Protalix BioTherapeutics Inc. (NYSEMKT:PLX) year to date (YTD) performance is 5.66%.
Receptos, Inc. (NASDAQ:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced the pricing of an underwritten public offering of 4,433,000 shares of its common stock at a price to the public of $40.25 per share. The gross proceeds to Receptos from this offering are expected to be approximately $178.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
Receptos Inc. (NASDAQ:RCPT) ended the last trading day at $40.99. Company weekly volatility is calculated as 6.60% and price to cash ratio as 5.73.Receptos Inc. (NASDAQ:RCPT) showed a positive weekly performance of 3.59%.
Acorda Therapeutics Inc. (NASDAQ:ACOR) on June 18 announced the pricing of a public offering of $300 million principal amount of convertible senior notes due 2021 (the “Notes”). The Notes will bear interest at an annual rate of 1.75% and will mature on June 15, 2021, unless earlier converted, purchased or redeemed. Acorda granted the underwriter an option to purchase up to an additional $45 million principal amount of Notes to cover over-allotments, if any. The Notes will be convertible prior to December 15, 2020 only under certain circumstances and during certain periods, and will be convertible thereafter regardless of those circumstances. Acorda Therapeutics Inc. (NASDAQ:ACOR) net profit margin is 5.30% and weekly performance is -0.57%. On last trading day company shares ended up $34.61. Analysts mean target price for the company is $40.35. Acorda Therapeutics Inc. (NASDAQ:ACOR) distance from 50-day simple moving average (SMA50) is 2.92%.